Back to results
US 11,236,391 B2Granted
Gene expression markers and treatment of multiple sclerosis
AssigneeGenentech, Inc.
InventorsMichael Townsend, Alvernia Francesca Setiadi, Tracy Staton
Life of this patent
Estimating the term…
Abstract
The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
Claims18
A method of treating a mammalian subject suffering from multiple sclerosis (MS), comprising:
- a) measuring, in a cerebrospinal fluid (CSF) sample of the subject, an expression level of tissue inhibitor of metalloproteinase 1 (TIMP1);
- b) comparing the expression level measured in a) to a reference expression level of TIMP1 in a CSF sample of an MS-negative control;
- c) identifying the subject as more likely to have an increased expression level of interleukin-17 (IL-17) as compared to an MS-negative control when the expression level measured in a) is above the reference expression level;
- and
- d) administering an effective amount of an IL-17 antagonist to the subject identified in c),
- wherein the IL-17 antagonist is an anti-IL-17 antibody or an anti-IL-17 receptor antibody.
3 more elements
A method of treating a mammalian subject suffering from multiple sclerosis (MS), comprising:
- administering an interleukin-17 (IL-17) antagonist to a subject who has been identified as more likely to have an increased expression level of IL-17 as compared to an MS-negative control, wherein the identification comprises detecting, in a cerebrospinal fluid (CSF) sample of the subject, an increased expression level of tissue inhibitor of metalloproteinase 1 (TIMP1) relative to a reference expression level of TIMP1 in a CSF sample of an MS-negative control, and wherein the IL-17 antagonist is an anti-IL-17 antibody or an anti-IL-17 receptor antibody.
Dependencies are inferred from the claim text.